et al., medRxiv, doi:10.1101/2020.11.29.20235218 (Preprint) (meta analysis - not included in study count)
6th independent analysis showing efficacy from the Boulware PEP trial.
This prospective analysis corrects an error in the NEJM paper where shipping delays are omitted (still not corrected).
42% reduction in COVID-19 (9.6% vs. 16.5%), RR 0.58 [0.35 - 0.97], p
=0.044, for the original trial 3 day specification.
Wiseman et al., 12/2/2020, preprint, 4 authors.
risk of COVID-19 case, 42.0% lower, RR 0.58, p = 0.04, <= 3 days after exposure.
Effect extraction follows pre-specified rules prioritizing more serious
outcomes. For an individual study the most serious outcome may have a smaller
number of events and lower statistical signficance, however this provides the
strongest evidence for the most serious outcomes when combining the results of